

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**  
**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Rivaroxaban for the prevention of adverse outcomes in patients  
after the acute management of acute coronary syndrome**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equalities issues were raised during the scoping workshop. During consultation of the draft scope one consultee commented on the trial that assessed rivaroxaban for this indication. They said that in common with other trials of drug treatment in ACS, older patients are usually excluded, and so we cannot be sure of the benefit/safety profile of rivaroxaban in these patients. In this respect, older patients are a 'disadvantaged' group because we do not have evidence upon which to judge their best treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This will be discussed by the Committee when considering the generalisability of the trial to the eligible population covered by the marketing authorisation for rivaroxaban for ACS.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope were required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified during the scoping process.

**Approved by Associate Director (name):** Janet Robertson.....

**Date:** 24th September 2012